NYSE: USNAUsana Health Sciences Inc Stock
$62.96-0.72 (-1.13%)
Updated Jun 9, 2023
USNA Price
$62.96
Fair Value Price
N/A
Market Cap
$1.22B
52 Week Low
$48.61
52 Week High
$76.58
P/E
18.57x
P/B
2.67x
P/S
1.25x
PEG
0.84x
Dividend Yield
N/A
Revenue
$974.09M
Earnings
$65.26M
Gross Margin
80.4%
Operating Margin
10.68%
Profit Margin
6.7%
Debt to Equity
0.33
Operating Cash Flow
$97M
Beta
0.76
Next Earnings
Jul 24, 2023
Ex-Dividend
N/A
Next Dividend
N/A
USNA Overview
USANA Health Sciences Incorporated manufactures nutritional and personal care products such as vitamin and mineral supplements, targeted supplements designed to meet cardiovascular, skeletal/structural, and digestive health needs, and meal replacement shakes, snack bars, and related products. USANA was founded in 1992 and is headquartered in Salt Lake City, UT.
Zen Score
–
Industry Average (34)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how USNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
USNA ($62.96) is trading above its intrinsic value of $44.44, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
USNA is good value based on its earnings relative to its share price (18.57x), compared to the US market average (52.94x)
P/E vs Market Valuation
USNA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more USNA due diligence checks available for Premium users.
Be the first to know about important USNA news, forecast changes, insider trades & much more!
USNA News
Valuation
USNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.57x
Industry
34.08x
Market
52.94x
USNA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
USNA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
USNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.67x
Industry
6.55x
USNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
USNA price to earnings growth (PEG)
For valuing profitable companies with growth potential
USNA is good value based... subscribe to Premium to read more.
PEG Value Valuation
USNA's financial health
Profit margin
Revenue
$248.4M
Net Income
$18.4M
Profit Margin
7.4%
USNA's Earnings (EBIT) of $104.03M... subscribe to Premium to read more.
Interest Coverage Financials
USNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$605.5M
Liabilities
$150.2M
Debt to equity
0.33
USNA's short-term assets ($395.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
USNA's short-term assets ($395.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
USNA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
USNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.8M
Investing
-$3.4M
Financing
-$3.2M
USNA's operating cash flow ($97.03M)... subscribe to Premium to read more.
Debt Coverage Financials
USNA vs Household & Personal Product Stocks
Usana Health Sciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.